Infertility Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End-User (Male and Female), Distribution Channel, and Geography

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.69 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The infertility drugs market studied was anticipated to register a CAGR of 6.1% during the forecast period. The major factors attributing to the growth of the market are significant changes in lifestyle which contributed to a rise in the number of (PCOS) Polycystic ovary syndrome cases, urinary, and breast cancers. The rise in the prevalence of cancers resulting in increased exposure to radiation which leads to infertility. As per the U.S. Department of Health and Human Services (HHS) report, in 2019, PCOS is a major health problem that affects 1 in 10 women of childbearing age across the globe. Thus, rising gynecological disorders resulting in decreased fertility rate is likely to fuel the global infertility drugs market.

Scope of the Report

Infertility is the inability of a woman to become pregnant after one year (or longer) of unprotected sex. The fertility rate decreases with the age of 35 or above in both men and women. Various drugs used to treat infertility are discussed in the report.

By Drug Class
Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End-user
Male
Female
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Female Infertility Drugs Segment is Expected to Hold the Major Market Share in the Infertility Drugs Market

The female infertility drugs segment is expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the higher incidences of infertility and misconception (as women are compared to men). The major cause of infertility among women is an increased prevalence of thyroid and breast cancer that necessitate higher exposure to radiation leading to a steep decrease in fertility rate. For instance, according to the factsheet published by the National Institutes of Health, the fertility rate of women decreases by half in their thirties. The report states that women's chance of conception declines significantly after age 35.6, whereas male fertility declines gradually and among the women with any type of cancer. The increase in the consumption of smoking and alcohol and the increasing incidence of various disorders, like PCOS and uterine fibroids, result in higher demand. This factor is expected to fuel the growth of the segment.

male-hypogonadism-market_Male_hypo_2.webp

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global infertility drugs market during the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, urinary infections, thyroid problems, endometriosis, and others due to busy lifestyles and a rise in stress among women. As per the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age. Also, a steep rise in oligozoospermia, varicocele, diabetes, and others among men in the United States propels the revenue share in the region. Additionally, the presence of more number of reproductive endocrinologists along with advanced healthcare infrastructure fuels the market growth in the United States. Government expenditure for the women healthcare awareness with growing geriatric women population and early product launches are expected to further contribute its outstanding share in the global market.

Mordor Intelligence

To understand geography trends, Download Sample Report

Competitive Landscape

The global infertility drugs market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the globe. Furthermore, a steep rise in the availability of public fundings to develop these drugs is also expected to fuel the market. In December 2019, Allergan announced that its product PrFIBRISTAL was publicly funded through the Ontario Drug Benefit (ODB) Formulary and the Non-Insured Health Benefits (NIHB) Program. PrFIBRISTAL is used in first-in-class medical treatment for uterine fibroids, which lead to infertility. The uterine fibroids are the most common gynecological tumors which affect almost one-in-three Canadian women of reproductive age. Such encouraging public funds, innovative approaches to treat infertility are likely to positively impact the market during the forecast period. Some of the companies which are currently dominating the market are Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., and Novartis AG

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of Stress and Life-style Disorders among Men and Women

      2. 4.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework that Delays the Approval of Products

      2. 4.3.2 Expensive Patented Products

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Gonadotrophins

      2. 5.1.2 Aromatase Inhibitors

      3. 5.1.3 Selective Estrogen Receptor Modulators (SERMs)

      4. 5.1.4 Biguanides

      5. 5.1.5 Other Drug Classes

    2. 5.2 By End-user

      1. 5.2.1 Male

      2. 5.2.2 Female

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Other Distribution Channels

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Takeda Pharmaceutical Company Limited

      3. 6.1.3 Ferring Pharmaceuticals Inc.

      4. 6.1.4 Merck KGaA.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Bayer AG

      8. 6.1.8 Theramex

      9. 6.1.9 Mankind Pharma

      10. 6.1.10 Teva Pharmaceticals Industries

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Infertility Drugs Market market is studied from 2018 - 2026.

The Infertility Drugs Market is growing at a CAGR of 4.69% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Ferring Pharmaceuticals Inc, Merck KGaA., Pfizer Inc., Novartis International AG, Bayer AG are the major companies operating in Infertility Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!